{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:46:14Z","timestamp":1777434374644,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"st jude children's research hospital cancer center support","award":["CA21765"],"award-info":[{"award-number":["CA21765"]}]},{"DOI":"10.13039\/100012524","name":"american lebanese syrian associated charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00280-021-04357-4","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T06:14:06Z","timestamp":1632896046000},"page":"1009-1020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Population pharmacokinetic analysis of crizotinib in children with progressive\/recurrent high-grade and diffuse intrinsic pontine gliomas"],"prefix":"10.1007","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6032-2528","authenticated-orcid":false,"given":"Elizabeth G.","family":"Gibson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6348-8910","authenticated-orcid":false,"given":"Olivia","family":"Campagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas S.","family":"Selvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar","family":"Gajjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1546-9720","authenticated-orcid":false,"given":"Clinton F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"4357_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fonc.2015.00237","volume":"5","author":"MI Vanan","year":"2015","unstructured":"Vanan MI, Eisenstat DD (2015) DIPG in children\u2014what can we learn from the past? Front Oncol 5:237. https:\/\/doi.org\/10.3389\/fonc.2015.00237","journal-title":"Front Oncol"},{"key":"4357_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fonc.2012.00105","volume":"2","author":"J Fangusaro","year":"2012","unstructured":"Fangusaro J (2012) Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol 2:105. https:\/\/doi.org\/10.3389\/fonc.2012.00105","journal-title":"Front Oncol"},{"issue":"6","key":"4357_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2217\/cns.14.43","volume":"3","author":"O Chamdine","year":"2014","unstructured":"Chamdine O, Gajjar A (2014) Molecular characteristics of pediatric high-grade gliomas. CNS Oncol 3(6):433\u2013443. https:\/\/doi.org\/10.2217\/cns.14.43","journal-title":"CNS Oncol"},{"issue":"30","key":"4357_CR4","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1200\/JCO.2011.35.5677","volume":"29","author":"BS Paugh","year":"2011","unstructured":"Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW, Baker SJ (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29(30):3999\u20134006. https:\/\/doi.org\/10.1200\/JCO.2011.35.5677","journal-title":"J Clin Oncol"},{"issue":"5","key":"4357_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00401-015-1405-4","volume":"129","author":"A Korshunov","year":"2015","unstructured":"Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA, Zheludkova O, Milde T, Witt O, Kulozik AE, Reifenberger G, Jabado N, Perry A, Lichter P, von Deimling A, Pfister SM, Jones DT (2015) Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129(5):669\u2013678. https:\/\/doi.org\/10.1007\/s00401-015-1405-4","journal-title":"Acta Neuropathol"},{"key":"4357_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0065-230X(06)97011-0","volume":"97","author":"A Ostman","year":"2007","unstructured":"Ostman A, Heldin CH (2007) PDGF receptors as targets in tumor treatment. Adv Cancer Res 97:247\u2013274. https:\/\/doi.org\/10.1016\/S0065-230X(06)97011-0","journal-title":"Adv Cancer Res"},{"issue":"10","key":"4357_CR7","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1101\/gad.1653708","volume":"22","author":"J Andrae","year":"2008","unstructured":"Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276\u20131312. https:\/\/doi.org\/10.1101\/gad.1653708","journal-title":"Genes Dev"},{"issue":"12","key":"4357_CR8","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1038\/s41419-017-0051-2","volume":"8","author":"E Papa","year":"2017","unstructured":"Papa E, Weller M, Weiss T, Ventura E, Burghardt I, Szabo E (2017) Negative control of the HGF\/c-MET pathway by TGF-beta: a new look at the regulation of stemness in glioblastoma. Cell Death Dis 8(12):3210. https:\/\/doi.org\/10.1038\/s41419-017-0051-2","journal-title":"Cell Death Dis"},{"issue":"36","key":"4357_CR9","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1200\/JCO.2011.37.7929","volume":"29","author":"LJ Appleman","year":"2011","unstructured":"Appleman LJ (2011) MET signaling pathway: a rational target for cancer therapy. J Clin Oncol 29(36):4837\u20134838. https:\/\/doi.org\/10.1200\/JCO.2011.37.7929","journal-title":"J Clin Oncol"},{"key":"4357_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27035","author":"A Broniscer","year":"2018","unstructured":"Broniscer A, Jia S, Mandrell B, Hamideh D, Huang J, Onar-Thomas A, Gajjar A, Raimondi SC, Tatevossian RG, Stewart CF (2018) Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.27035","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"4357_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40262-018-0689-7","volume":"58","author":"T Hirota","year":"2019","unstructured":"Hirota T, Muraki S, Ieiri I (2019) Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Clin Pharmacokinet 58(4):403\u2013420. https:\/\/doi.org\/10.1007\/s40262-018-0689-7","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"4357_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","volume":"59","author":"D Leveque","year":"2020","unstructured":"Leveque D, Becker G, Bilger K, Natarajan-Ame S (2020) Clinical pharmacokinetics and pharmacodynamics of dasatinib. Clin Pharmacokinet 59(7):849\u2013856. https:\/\/doi.org\/10.1007\/s40262-020-00872-4","journal-title":"Clin Pharmacokinet"},{"key":"4357_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jchromb.2014.04.035","volume":"960","author":"MS Roberts","year":"2014","unstructured":"Roberts MS, Turner DC, Broniscer A, Stewart CF (2014) Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization-tandem mass spectrometry (LC\u2013ESI\u2013MS\/MS). J Chromatogr B Analyt Technol Biomed Life Sci 960:151\u2013157. https:\/\/doi.org\/10.1016\/j.jchromb.2014.04.035","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"11","key":"4357_CR14","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-13-0306","volume":"19","author":"A Broniscer","year":"2013","unstructured":"Broniscer A, Baker SD, Wetmore C, Panandiker ASP, Huang J, Davidoff AM, Onar-Thomas A, Panetta JC, Chin TK, Merchant TE, Baker JN, Kaste SC, Gajjar A, Stewart CF (2013) Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res 19(11):3050\u20133058. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0306","journal-title":"Clin Cancer Res"},{"key":"4357_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4","author":"DR Mould","year":"2012","unstructured":"Mould DR, Upton RN (2012) Basic concepts in population modeling, simulation, and model-based drug development. CPT. https:\/\/doi.org\/10.1038\/psp.2012.4","journal-title":"CPT"},{"issue":"5","key":"4357_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481\u2013504","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4357_CR17","unstructured":"Weight-for-age charts, 2 to 20 years, LMS parameters and selected smoothed weight percentiles in kilograms, by sex and age (2013) CDC (Centers for Disease Control and Prevention). http:\/\/www.cdc.gov\/growthcharts\/percentile_data_files.htm. Accessed 19 Jun 2021"},{"key":"4357_CR18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00467-017-3693-5","volume":"32","author":"VE Millisor","year":"2017","unstructured":"Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, Gregornik D, Cross SJ, Ward D, Pauley JL, Molinelli A, Brennan RC, Stewart CF (2017) Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients. Pediatr Nephrol 32:1575\u20131584. https:\/\/doi.org\/10.1007\/s00467-017-3693-5","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4357_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10928-013-9343-z","volume":"41","author":"HT Thai","year":"2014","unstructured":"Thai HT, Mentre F, Holford NH, Veyrat-Follet C, Comets E (2014) Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics. J Pharmacokinet Pharmacodyn 41(1):15\u201333. https:\/\/doi.org\/10.1007\/s10928-013-9343-z","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"4357_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"issue":"23","key":"4357_CR21","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.1158\/1078-0432.CCR-16-0536","volume":"22","author":"E Wang","year":"2016","unstructured":"Wang E, Nickens DJ, Bello A, Khosravan R, Amantea M, Wilner KD, Parivar K, Tan W (2016) Clinical implications of the pharmacokinetics of crizotinib in populations of patients with non-small cell lung cancer. Clin Cancer Res 22(23):5722\u20135728. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0536","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4357_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00280-016-3220-6","volume":"79","author":"FM Balis","year":"2017","unstructured":"Balis FM, Thompson PA, Mosse YP, Blaney SM, Minard CG, Weigel BJ, Fox E (2017) First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children\u2019s Oncology Group Phase 1\/Pilot Consortium. Cancer Chemother Pharmacol 79(1):181\u2013187. https:\/\/doi.org\/10.1007\/s00280-016-3220-6","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4357_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00280-020-04171-4","volume":"86","author":"E Greengard","year":"2020","unstructured":"Greengard E, Mosse YP, Liu X, Minard CG, Reid JM, Voss S, Wilner K, Fox E, Balis F, Blaney SM, Adamson PC, Weigel BJ (2020) Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children\u2019s Oncology Group phase 1 consortium study (ADVL1212). Cancer Chemother Pharmacol 86(6):829\u2013840. https:\/\/doi.org\/10.1007\/s00280-020-04171-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"4357_CR24","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","volume":"15","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15(19):6232\u20136240. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0224","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4357_CR25","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.pcl.2017.08.011","volume":"64","author":"Y Xiong","year":"2017","unstructured":"Xiong Y, Fukuda T, Knibbe CAJ, Vinks AA (2017) Drug dosing in obese children: challenges and evidence-based strategies. Pediatr Clin North Am 64(6):1417\u20131438. https:\/\/doi.org\/10.1016\/j.pcl.2017.08.011","journal-title":"Pediatr Clin North Am"},{"key":"4357_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010814-124354","volume":"55","author":"CA Knibbe","year":"2015","unstructured":"Knibbe CA, Brill MJ, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M (2015) Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol 55:149\u2013167. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010814-124354","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"4357_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00280-018-3517-8","volume":"81","author":"AB El-Khoueiry","year":"2018","unstructured":"El-Khoueiry AB, Sarantopoulos J, O\u2019Bryant CL, Ciombor KK, Xu H, O\u2019Gorman M, Chakrabarti J, Usari T, El-Rayes BF (2018) Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemother Pharmacol 81(4):659\u2013670. https:\/\/doi.org\/10.1007\/s00280-018-3517-8","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04357-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04357-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04357-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T17:02:57Z","timestamp":1634922177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04357-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4357"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04357-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"19 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no conflict of interest in this work. During the entire time of the analysis of the clinical data and of the preparation of the manuscript, Dr. Gibson was working at St Jude Children\u2019s Research Hospital. The Bristol Myers Squibb company was not involved in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the St. Jude Children\u2019s Research Hospital Institutional Review Board and with the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Permission has been obtained from all named authors to submit the manuscript for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}